Kyle Doherty

Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.

Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.

Primary payer data reported by cancer registries are subject to measurement error and can result in biased estimates of insurance-related policy effects.

National Cancer Institute-designated comprehensive cancer centers routinely perform clinical trial site self-assessments. However, participation in these types of assessments is far less commonplace among community oncology sites.

HER3 has been shown to have a small amount of tyrosine kinase activity, making it an attractive target for the treatment of patients who have progressed after treatment with tyrosine kinase inhibitors. Preclinical data have shown that targeting HER3 and EGFR can overcome acquired resistance to EGFR inhibition.

Sara A. Hurvitz, MD, explains when de-escalation therapy can play a role in patients with HER2-positive breast cancer.

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

Joyce O'Shaughnessy, MD, outlines the current role and ongoing research of CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative early stage breast cancer.

Major pathological response and recurrence-free survival rates were improved in women vs men with melanoma who received BRAF/MEK inhibitor therapy in the neoadjuvant setting.

The expansion of technology includes machine learning, which is quickly emerging as a dynamic aid for clinicians in every aspect of cancer care, from diagnosis to treatment decisions.

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Patients with platinum-resistant ovarian cancer have historically been an underserved population with few effective treatment options.

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Venetoclax plus obinutuzumab remains an effective fixed-duration treatment option for patients with chronic lymphocytic leukemia and coexisting conditions, according to updated efficacy and safety data from the ongoing phase 3 CLL14 trial.

The phase 3 BRUIN CLL-313 trial is currently recruiting patients with treatment naïve chronic lymphocytic leukemia or small lymphocytic lymphoma to evaluate the efficacy and safety of pirtobrutinib monotherapy vs bendamustine plus rituximab.

The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.

Epcoritamab in combination with gemcitabine plus oxaliplatin displayed encouraging responses with no new safety signals among patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant, according to initial results from the phase 1b/2 EPCORE NHL-2 trial.

The BRUIN CLL-321 trial is evaluating pirtobrutinib monotherapy compared with investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received covalent BTK inhibitor treatment.

Patritumab deruxtecan exhibited promising clinical activity in heavily pretreated patients with advanced non-small cell lung cancer without EGFR-activating mutations, including activity in patients with other identified driver genomic alterations.

Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.

First-line treatment with palbociclib plus letrozole did not elicit a significant benefit in overall survival compared with letrozole monotherapy in patients with estrogen receptor-positive/HER2-negative advanced breast cancer missing the secondary end point of the trial.

Galinpepimut-S in combination with the PD-1 inhibitor pembrolizumab elicited a clinical benefit in patients with Wilms’ tumor-1-positive relapsed/refractory platinum-resistant advanced metastatic ovarian cancer, according to top line-line data from a phase 1/2 trial (NCT03761914).

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.

Increased spending on state public welfare programs was associated with a higher 5-year overall survival rate among Black patients.

Amplification of murine double minute 2 represents a promising target to access the so-called cellular gatekeeper p53 protein in human cancers.

For decades in cancer care, the compiling of patient-reported outcomes was limited to simple standardized questionnaires completed with pen and paper.

The FDA has approved pembrolizumab in patients with advanced endometrial cancer that is microsatellite instability-high or mismatch repair–deficient and who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

TROP-2 and Nectin-4, surface cell targets of sacituzumab govitecan and enfortumab vedotin, respectively, are highly expressed in urothelial cancer and variant histology bladder cancer.

The novel, near-infrared, prostate-specific membrane antigen-targeted fluorophore IS-002 was safe, well-tolerated, and allowed for enhanced intraoperative tumor detection in patients undergoing robotic prostatectomy.